1,905 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by Headlands Technologies LLC

Headlands Technologies LLC bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,905 shares of the company’s stock, valued at approximately $48,000.

A number of other large investors have also made changes to their positions in BBIO. Wellington Management Group LLP increased its position in shares of BridgeBio Pharma by 5.3% during the fourth quarter. Wellington Management Group LLP now owns 1,495,114 shares of the company’s stock worth $60,358,000 after acquiring an additional 75,564 shares in the last quarter. UBS Group AG increased its position in BridgeBio Pharma by 545.9% during the fourth quarter. UBS Group AG now owns 985,510 shares of the company’s stock worth $39,785,000 after acquiring an additional 832,940 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of BridgeBio Pharma by 22.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 803,956 shares of the company’s stock worth $24,859,000 after purchasing an additional 145,594 shares during the period. Vanguard Group Inc. increased its stake in BridgeBio Pharma by 3.3% during the 1st quarter. Vanguard Group Inc. now owns 13,222,126 shares of the company’s stock worth $408,828,000 after acquiring an additional 421,832 shares during the period. Finally, ADAR1 Capital Management LLC bought a new position in shares of BridgeBio Pharma in the fourth quarter worth $7,474,000. Institutional investors own 99.85% of the company’s stock.

Analysts Set New Price Targets

BBIO has been the subject of a number of research analyst reports. UBS Group lowered their price target on BridgeBio Pharma from $51.00 to $47.00 and set a “buy” rating for the company in a report on Tuesday, May 28th. HC Wainwright restated a “buy” rating and set a $43.00 price objective on shares of BridgeBio Pharma in a research report on Monday. Bank of America reissued a “buy” rating and set a $42.00 target price on shares of BridgeBio Pharma in a research note on Wednesday, September 11th. Piper Sandler started coverage on BridgeBio Pharma in a research note on Wednesday, September 4th. They issued an “overweight” rating and a $46.00 price target on the stock. Finally, JPMorgan Chase & Co. cut their price objective on shares of BridgeBio Pharma from $46.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $47.92.

BridgeBio Pharma Trading Up 0.0 %

BBIO stock opened at $26.19 on Tuesday. The stock’s fifty day simple moving average is $26.50 and its two-hundred day simple moving average is $27.30. The stock has a market cap of $4.90 billion, a P/E ratio of -8.13 and a beta of 1.07. BridgeBio Pharma, Inc. has a 1-year low of $21.62 and a 1-year high of $44.32.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.61. The firm had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $3.96 million. The firm’s quarterly revenue was up 32.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.98) EPS. As a group, analysts forecast that BridgeBio Pharma, Inc. will post -2.49 earnings per share for the current fiscal year.

Insider Activity at BridgeBio Pharma

In related news, CFO Brian C. Stephenson sold 4,155 shares of the stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $24.69, for a total transaction of $102,586.95. Following the sale, the chief financial officer now owns 85,192 shares of the company’s stock, valued at approximately $2,103,390.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other BridgeBio Pharma news, CFO Brian C. Stephenson sold 4,155 shares of the firm’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $24.69, for a total value of $102,586.95. Following the sale, the chief financial officer now owns 85,192 shares of the company’s stock, valued at approximately $2,103,390.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Neil Kumar sold 27,389 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $24.69, for a total transaction of $676,234.41. Following the completion of the transaction, the chief executive officer now directly owns 4,897,443 shares of the company’s stock, valued at approximately $120,917,867.67. The disclosure for this sale can be found here. 24.66% of the stock is currently owned by corporate insiders.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.